Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT
Authors:
- China HepB-Related Fibrosis Assessment Research GroupCGChina HepB-Related Fibrosis Assessment Research Group
- Linlin YanLYLinlin Yan
- Yongqiong DengYDYongqiong Deng
- Jiyuan ZhouJZJiyuan Zhou
- Hong ZhaoHZHong Zhao
- Guiqiang WangGWGuiqiang Wang
Open Access
- 29 March 2018
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 46 (3) , 385-393
Abstract
Purpose YKL-40 is a chitinase-like protein expressed in multiple tissues including liver and is reported as a fibrosis marker. This study aimed to determine whether YKL-40 could serve as a diagnostic marker for the assessment of liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Methods Six hundred and eighty-five patients with chronic hepatitis B infection were enrolled in this study from October 2013 to March 2016. All patients underwent liver biopsy and then staged based on Ishak histological system. Serum YKL-40 levels were measured by Human Magnetic Luminex Assays. Results Among chronic hepatitis B patients with normal and mildly elevated ALT, almost more than 30% of patients have significant liver fibrosis. Serum YKL-40 levels increased significantly in parallel with the progression of fibrosis in patients with ALT less than two times the upper limit of normal range (P < 0.0001). Multivariate analysis revealed that serum YKL-40, hyaluronic acid, PLT, and AST were independently associated with significant fibrosis. We established a novel YKL-40-based fibrosis model for patients with ALT less than two times the upper limit of normal range (ULN). YKL-40 model was superior to APRI, FIB-4, Forns’ index, and Hui model for diagnosis of significant fibrosis in patients with ALT < 2ULN, with AUROCs of 0.786 [95% confidence interval (CI) 0.726–0.846] in the training group, 0.831 (95%CI 0.752–0.910) in the validation group and 0.801 (95%CI 0.753–0.849) in the entire cohort. Conclusion Serum YKL-40 is a feasible biomarker of liver fibrosis in chronic hepatitis B patients. YKL-40 model was superior to APRI, FIB-4, Forns’ index and Hui model for diagnosis of significant fibrosis in patients with normal and mildly elevated ALT.Keywords
Funding Information
- China Mega-Project for Infectious Diseases (2013ZX10002005, 2012ZX10002006, 2013ZX10002004, 2012ZX10005005)
- Project of Beijing Science and Technology Committee (D121100003912002)
This publication has 42 references indexed in Scilit:
- Feasibility study and control values of transient elastography in healthy childrenEuropean Journal of Pediatrics, 2011
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALTGastroenterology, 2008
- Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis CHepatology, 2008
- The clinical significance of persistently normal ALT in chronic hepatitis B infectionJournal of Hepatology, 2007
- Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver diseaseLiver International, 2005
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive modelHepatology, 2002
- YKL-40 (Cartilage gp-39) Induces Proliferative Events in Cultured Chondrocytes and Synoviocytes and Increases Glycosaminoglycan Synthesis in ChondrocytesBiochemical and Biophysical Research Communications, 2001
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995